Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes - Concepedia

Concepedia

Publication | Open Access

Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

DOI Full Paper Access

12

Citations

5

References

2023

Year

John Mascarenhas, Claire Harrison, Tammy A. Schuler, Djibril Liassou, Marné Garretson, Taavy A. Miller, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis,

Clinical Lymphoma Myeloma & Leukemia

Abstract

Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.

References

	Year	Citations

Page 1